Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01617148
Recruitment Status : Completed
First Posted : June 12, 2012
Results First Posted : July 25, 2018
Last Update Posted : July 25, 2018
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Rishi Singh, The Cleveland Clinic

Brief Summary:
This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.

Condition or disease Intervention/treatment Phase
Exudative Macular Degeneration Drug: Aflibercept Phase 4

Detailed Description:
The purpose of this study is to examine the use of Aflibercept in patients who have been previously treated with Ranibizumab or Bevacizumab for exudative macular degeneration. Specifically, we will examine its effect on macular degeneration, measured by SDOCT (Spectral Domain Optical Coherence Tomography) and ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity. This will be a prospective study with patients to receive an intravitreal injection of Aflibercept at the time of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Study Start Date : June 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment with Aflibercept
Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
Drug: Aflibercept
Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.




Primary Outcome Measures :
  1. Change in Central Subfield Thickness From Baseline at 12 Months [ Time Frame: baseline and 12 months ]
    The mean absolute change from baseline central subfield thickness at 12 months as measured by SDOCT


Secondary Outcome Measures :
  1. Change in Best-corrected Visual Acuity From Baseline at 12 Months [ Time Frame: Baseline and 12 months ]
    The mean absolute change from baseline in best-corrected visual acuity score at 12 months as measured by Eletronic-Early Treatment in Diabetic Retinopathy Scale (E-ETDRS) protocol. There were no sub scales used. These are common methods for ophthalmology studies to report their findings. The scale provided is the Electronic-Early Treatment in Diabetic Retinopathy Scale (E-ETDRS) best corrected visual acuity scale. Values that are higher are considered better and values that are lower are considered worse. Minimum E-ETDRS was 24 E-ETDRS letters and maximum E-ETDRS was 80 E-ETDRS letters.

  2. Change in Macular Volume From Baseline at 12 Months. [ Time Frame: baseline and 12 months ]
    Mean absolute change from baseline in macular volume at 12 months.

  3. Change in Cube Average Thickness From Baseline at 12 Months [ Time Frame: baseline and 12 months ]
    Mean absolute change in cube average thickness as measured by SDOCT from baseline at 12 months.

  4. Percentage of Patients Who Gained Greater Than 15 Letters of Vision From Baseline at 12 Months. [ Time Frame: baseline and 12 months ]
    The percentage of patients who gained greater than 15 letters of vision from baseline to 12 months.

  5. Percentage of Patients Who Lost Greater Than 15 Letters of Vision From Baseline at 12 Months [ Time Frame: baseline and 12 months ]
    The percentage of patients who lost greater than 15 letters of vision from baseline at 12 months.

  6. Percentage of Subjects Who Were 20/40 or Better at Month 12. [ Time Frame: month 12 ]
    Percentage of subjects who had vision acuity of 20/40 or better at month 12.

  7. Percentage of Subjects Who Were 20/200 or Worse at Month 12. [ Time Frame: month 12 ]
    Percentage of subjects who had visual acuity of 20/200 or worse at month 12.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

A subject must meet the following criteria to be eligible for inclusion in the study:

  1. Signed Informed Consent.
  2. Men and women ≥ 50 years of age.
  3. Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by historical optical coherence tomographies (OCTs) and angiograms in the study eye.
  4. CNV must be at least 50% of total lesion size by either previous or current angiogram.
  5. ETDRS best-corrected visual acuity of: 20/25 to 20/320 (letter score of 73 to 25) in the study eye.
  6. Willing, committed, and able to return for all clinic visits and complete all study related procedures.
  7. At least one injection of Ranibizumab or Bevacizumab within 3 months of enrollment for active exudative AMD.
  8. Active need for anti- vascular endothelial growth factor (anti-VEGF) therapy at study entry based on the following criteria:

    1. Presence of fluid by either optical coherence tomography (OCT) or clinical examination (further defined as intraretinal, cystoid, subretinal, worsening pigment epithelial detachment)
    2. Presence of new hemorrhage on clinical examination

Exclusion Criteria

A subject who meets any of the following criteria will be excluded from the study:

  1. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins.
  2. Prior systemic anti-VEGF therapy, investigational or FDA/Health Canada approved, is only allowed up to 3 months prior to first dose, and will not be allowed during the study.
  3. Presence of retinal pigment epithelial tears or rips involving the macula in the study
  4. History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
  5. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25 mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye.
  6. History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye.
  7. Prior vitrectomy in the study eye.
  8. History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
  9. Any history of macular hole of stage 2 and above in the study eye.
  10. Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as it's unlikely to interfere with the injection.
  11. Prior trabeculectomy or other filtration surgery in the study eye.
  12. Uncontrolled glaucoma at baseline evaluation (defined as intraocular pressure ≥25 mmHg despite treatment with anti-glaucoma medication) in the study eye.
  13. Active intraocular inflammation in either eye.
  14. Active ocular or periocular infection in either eye.
  15. Any ocular or periocular infection within the last 2 weeks prior to Screening in either eye.
  16. Any history of uveitis in either eye.
  17. Active scleritis or episcleritis in either eye.
  18. Presence or history of scleromalacia in either eye.
  19. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye.
  20. Previous therapeutic radiation in the region of the study eye.
  21. History of corneal transplant or corneal dystrophy in the study eye.
  22. Significant media opacities, including cataract, in the study eye which might interfere with visual acuity, assessment of safety, or fundus photography.
  23. Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the opinion of the investigator, could require either medical or surgical intervention during the 52 week study period.
  24. Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.
  25. Participation as a subject in any clinical study within the 12 weeks prior to Day 1.
  26. Any systemic with an investigational agent in the past 3 months prior to Day 1.
  27. The use of long acting intraocular steroids or photodynamic therapy in the 6 months prior to day 1.
  28. Any history of allergy to povidone iodine.
  29. Pregnant or breast-feeding women
  30. Women of childbearing potential* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)

    • *Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01617148


Locations
Layout table for location information
United States, Ohio
Cole Eye Institute, Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Rishi Singh
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Rishi P Singh, MD The Cleveland Clinic

Publications of Results:
Layout table for additonal information
Responsible Party: Rishi Singh, MD, The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT01617148     History of Changes
Other Study ID Numbers: VGFTe-AMD-1211
First Posted: June 12, 2012    Key Record Dates
Results First Posted: July 25, 2018
Last Update Posted: July 25, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Rishi Singh, The Cleveland Clinic:
Exudative Macular Degeneration
Aflibercept

Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Bevacizumab
Ranibizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors